The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing, and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease, and Alzheimer’s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionized the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centers in Denmark and China.

AntiCancer, Inc. operates as a biotechnology company. It develops drugs for cancer based on genetic engineering and targeting cancer specific metabolic defects. The company provides Oncobriteâ, a small-animal imaging technology; MetaMouseâ and ANGIOMOUSEâ that are mouse models of human cancer; Histoculture Drug Response Assay, an individualized cancer therapy; Oncase-PEGâ, a recombinant protein that depletes methionine in tumors; stem cells for general regenerative medicine; tumor-targeting bacteria; and Dermatek, a liposome-based hair-follicle targeting technology. It also offers Enzymatic Homocysteine, Enzymatic B6, and Enzymatic cysteine assays.

Health & Biotech is a biotechnology company that provides diversified products and services. The company specializes in placenta-umbilical cord-derived stem cell storage, and research. and application. Its product catalog includes cell therapy, tissue engineering, and biological skin care products and offers services like stem cell banking, CDMO, functional evaluation, and research cooperation.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Beijing Yinfeng Dingcheng Bioengineering Technology Co., Ltd., established on 2015-07-31, Business scope includes new stem cell drugs,Adult Autologous Applied Cell Bank,stem cell therapy,human stem cells,Cell Technology Development,technology transfer,Technology Exchange,technical consulting,Technical Services;Sales of chemical reagents,Chemical Products,medical instrumentsIkind;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Production No.Iclass of medical devices;Technology Import and Export;Sales No.IIIclass of medical devices.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Sales No.IIIClass medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Beijing Han's Stem Cell Technology Co., Ltd., established on 2020-03-06, The business scope includes the sale of third-class medical devices;cell medicine,gene medicine,Technology development in biomedical technology,technical consulting,technology transfer,Technical Services;sell cosmetics,Instrumentation,Chemical Products,Class of medical equipment,Class II,Mechanical equipment and its spare parts;production of cellular medicines,Class of medical equipment,Class II,Three categories(limited branch production);Import and export,Technology Import and Export,Agent import and export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Sales of Class III medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Beijing Saier Regenerative Medicine Biotechnology Co., Ltd., established on 2011-11-29, Business scope includes human stem cells,cell technology,Biotechnology,Biological Engineering,Cell and Bioengineering Products,Cell Preparation and Storage,cell engineering,Cell Series Technology Engineering,cell therapy,cell antibody,cell medicine,Genetic Testing,gene medicine,Health products,cosmetic,Diagnostic reagents,medical instruments,Technical development of scientific research biological antibodies and laboratory kits,technical consulting,Technology Exchange,technology transfer,Technology Promotion,Technical Services,Technical testing;software development;Medical Research and Experimental Development;Natural science research and experimental development;hospital management(Does not include medical activities);health management(Except for medical treatment activities subject to approval);Sales of disinfection products,Chemical Products(No licensed chemical products),cosmetic,daily necessities,medical instrumentsIkind,IIkind;Import and export,Technology Import and Export,Import and export agency;Drug Wholesale;Production of Class II Medical Devices;Production of Class III Medical Devices;career brokerage;pharmaceutical production(Manufacturing of chemical raw materials,Manufacturing of Veterinary Drugs,Except for the processing of Chinese herbal decoction pieces);Class III medical device business;Drug retail.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Drug Wholesale,Production of Class II Medical Devices,Production of Class III Medical Devices,career brokerage,pharmaceutical production(Manufacturing of chemical raw materials,Manufacturing of Veterinary Drugs,Except for the processing of Chinese herbal decoction pieces),Class III medical device business,Drug retail and legally subject to approval items,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Weihai Jiansheng Biotechnology Co., Ltd., established on 2019-06-12, Business scope includes medical research and experimental development;Medical service;Biotechnology R&D,to promote;cosmetic,Sales of health care products;Medical Device Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Dongguk University Industry-Academic Cooperation Foundation is for the promotion of tenants and entrepreneurship.

Tianjin Kangting Bioengineering Group Co., Ltd., established on 1996-09-09, Business scope includes cosmetics,Production of hygiene products,manufacture,processing,Sales;Sell ​​dropshipping products in dropshipping style142kind(The product list is subject to the direct sales product list approved by the Ministry of Commerce);food production,Sales;Wujinjiaodian,Chemical Products(Hazardous chemicals and precursor chemicals are excluded),Daily necessities,building materials,Decoration materials,department store,household appliances,Health Products Sales;Hotel Management Services;General cargo transportation;Business Management Consulting Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Riken Corp. engages in the manufacture and sale of engine and vehicular components. It operates through the Automotive and Machinery Parts, and Others segments. The Automotive and Machinery Parts segment deals with the company's core products such as piston rings, camshafts, seal rings for transmissions, high-grade cast iron products, and valve lifters. The Others segment includes plumbing equipment business, Electromagnetic Compatibility (EMC) business, and thermal engineering business, The company was founded by Masatoshi Okochi in November 1927 and is headquartered in Tokyo, Japan.

Manufactures and sells pharmaceuticals

International Stem Cell Corp. operates as a research and development company for the therapeutic market. It focuses on advancing potential clinical applications of human parthenogenetic stem cells for the treatment of various diseases of the central nervous system and liver diseases. The firm operates through three segments: Therapeutic Market, Biomedical Market and Anti-Aging Market. The Biomedical Market segment markets and sells primary human cell research products with two product categories, cells and media. The Anti-Aging market segment markets and sells a line of skincare products sold through two sales channels: ecommerce and professional. The ecommerce channel sells direct to customers through online orders, while professional sales are to spas, salons and other skincare providers. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich and Gregory S. Keller in June 2005 and is headquartered in San Diego, CA.

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.